Trial Profile
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 When co-Administered With GSK Biologicals' MMRV Vaccine (Priorix-Tetra) in Healthy 12 to 23-Month-Old Children
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Jul 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine group C conjugate; MMR-varicella zoster virus vaccine
- Indications Meningococcal infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 26 Mar 2011 Primary endpoint 'Seroconversion-rate' has been met.
- 26 Mar 2011 Primary endpoint 'Immunological-response' has been met (3052612).
- 25 Mar 2011 Results published in Vaccine.